BioAdaptives (BDPT) Stock Statistics & Valuation Metrics
Total Valuation
BioAdaptives has a market cap or net worth of $236.31K. The enterprise value is $418.80B.
- Market Cap
- $236.31K
- Enterprise Value
- $418.80B
Share Statistics
BioAdaptives has 196,926,760 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 196,926,760
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
BioAdaptives’s return on equity (ROE) is 0.73 and return on invested capital (ROIC) is 59.70%.
- Return on Equity (ROE)
- 0.73
- Return on Assets (ROA)
- -6.90
- Return on Invested Capital (ROIC)
- 59.70%
- Return on Capital Employed (ROCE)
- 0.49
- Revenue Per Employee
- 18.28K
- Profits Per Employee
- -1.56M
- Employee Count
- 1
- Asset Turnover
- 0.08
- Inventory Turnover
- 0.13
Valuation Ratios
The current PE Ratio of BioAdaptives is -0.01. BioAdaptives’s PEG ratio is 0.00.
- PE Ratio
- -0.01
- PS Ratio
- 9.25
- PB Ratio
- -0.01
- Price to FCF
- -0.84
- Price to Operating Cash Flow
- -0.06
- PEG Ratio
- 0.00
Income Statement
In the last 12 months, BioAdaptives had revenue of 18.28K and earned -1.56M in profits. Earnings per share was -0.15.
- Revenue
- 18.28K
- Gross Profit
- 12.50K
- Operating Income
- -1.04M
- Pretax Income
- -1.56M
- Net Income
- -1.56M
- EBITDA
- -1.48M
- Earnings Per Share (EPS)
- -0.15
Cash Flow
In the last 12 months, operating cash flow was -280.51K and capital expenditures 0, giving a free cash flow of -280.51K billion.
- Operating Cash Flow
- -280.51K
- Free Cash Flow
- -280.51K
- Free Cash Flow per Share
- -0.02
Dividends & Yields
BioAdaptives pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -118.70%
- Earnings Yield
- -6834.46%
Stock Price Statistics
- Beta
- -0.99
- 52-Week Price Change
- -72.50%
- 50-Day Moving Average
- 0.01
- 200-Day Moving Average
- 0.02
- Relative Strength Index (RSI)
- ―
- Average Volume (3m)
- ―
Financial Position
BioAdaptives as a current ratio of 0.09, with Debt / Equity ratio of -18.05%
- Current Ratio
- 0.09
- Quick Ratio
- 0.07
- Debt to Market Cap
- 1.73
- Net Debt to EBITDA
- -0.15
- Interest Coverage Ratio
- -14.70
Taxes
In the past 12 months, BioAdaptives has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
BioAdaptives EV to EBITDA ratio is -0.57, with an EV/FCF ratio of -2.60.
- EV to Sales
- 28.55
- EV to EBITDA
- -0.57
- EV to Free Cash Flow
- -2.60
- EV to Operating Cash Flow
- -2.60
Balance Sheet
BioAdaptives has $29.22K in cash and marketable securities with $522.73K in debt, giving a net cash position of -$493.50K billion.
- Cash & Marketable Securities
- $29.22K
- Total Debt
- $522.73K
- Net Cash
- -$493.50K
- Net Cash Per Share
- $0.00
- Tangible Book Value Per Share
- -$0.12
Margins
Gross margin is 74.48%, with operating margin of -3551.11%, and net profit margin of -4553.73%.
- Gross Margin
- 74.48%
- Operating Margin
- -3551.11%
- Pretax Margin
- -4553.73%
- Net Profit Margin
- -4553.73%
- EBITDA Margin
- -5049.76%
- EBIT Margin
- -5366.65%
Analyst Forecast
The average price target for BioAdaptives is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- 0
- Revenue Growth Forecast
- 694.07%
- EPS Growth Forecast
- -55.67%
